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EDITORIAL
The way to obtain and maintain a culture of mice
embryo stem cells has been known for about 25
years (1). In late 1998, after intense experimenta-
tion work, a group of Wisconsin University resear-
chers obtained the first culture of human embryo
stem cells (2). As of that time, stem cells have been
presented as the great therapeutic hope of the new
century. The human embryo stem cells are immor-
tal and have almost unlimited development poten-
tial. After remaining months in a culture, said cells
maintain the ability to differentiate into any type of
cell. This proliferation and differentiation capacity
carries the promise of supplying specific cell types
for basic research or therapeutic transplant for
application to various types of pathologies such as
heart disorders, leukemia, diabetes, Parkinson’s or
retinal degenerative diseases.
The main applications in stem cell research are:
the identification of action mechanisms of various
drugs and the assessment of their therapeutic poten-
tial, the understanding, prevention and treatment of
congenital diseases, the study of cell differentiation
at the basic research level and the obtainment of tis-
sues and cells for transplants. After achieving the
differentiation of stem cells in a specific type of
precursor or mature cell, it could be utilized for
some human diseases caused by the death or dys-
function of a specific cell type (dopaminergic neu-
rons in Parkinson’s, insulin-producing cells in dia-
betes, photoreceptors in pigmentary retinosis or
retinal pigmentary epithelium) in ARMD.
The lines of human embryo stem cells are not the
only source of cells for therapeutic use. For instan-
ce, neuronal precursors for the retina can be obtai-
ned from the eyes of fetus which did not complete
their development, from hematopoietic cells and the
umbilical cord. The literature has also described the
possibility of multipotential retinal cells in the pars
plana of the ciliar body in human adults (3), as is
the case in other vertebrate species such as amphi-
bians or fish.
The use of human embryo and fetal cells in cell
therapy has given rise to ethical and social issues, in
addition to the technical difficulties involves in
obtaining the effective integration of said cells in
the recipient tissue at the morphological and func-
tional level. 
Many questions remain to be answered about
controlled differentiation of stem cells to form a
given cell type. It is known that stem and progeni-
tor cells receive instructions from specific regula-
tory genes as well as obtaining information from
their environment. These signals determine the des-
tiny of said cells and the type of tissue they will ori-
ginate. Embryo stem cells can form embryoid
bodies in culture and can be directed towards neu-
ral differentiation by adding retinoic acid of FGF2
to the culture medium after a proliferation phase in
the presence of various factors. The subsequent dif-
ferentiation into retinal neurons can be achieve by a
joint culture with retinal cells or overexposure of
some regulatory gene (such as Crx).
Stem cells which differentiate into various neuro-
nal types o retinal pigmentary epithelium have been
utilized in cell therapy on various animal models of
pigmentary retinosis, generally obtaining an impro-
vement in functional response and anatomic preser-
vation (4). Recently, researchers have observed the
establishment of correct synaptic connections after
transplanting rod-precursor postnatal cells in blind
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mice (5). Even though numerous problems remain
to be solved for effectively applying said cells in
patients, including ethical and legal barriers, substi-
tution therapy with stem cells holds a promising
outlook for treating a large number of retinal neu-
rodegenerative diseases.
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